#### **SUPPLEMENTARY TABLES**

## Supplementary Table S1: Baseline characteristics of patients from 1st data set

Patients' characteristics	Number (%)			
Age, years	Median (range)	59 (26–84)		
Gender	Male Female	216 (62.6%) 129 (37.4%)		
Baseline laboratory findings at diagnosis	Hemoglobin (g/dL) MCV (fL) Hemoglobin ≤11 g/dL, number (%)	$13.18 \pm 1.95$ $89.67 \pm 6.81$ 49 (14.2%)		
Disease	Gastric cancer Colorectal cancer Hepatocellular carcinoma Lung cancer	101 (29.3%) 69 (20.0%) 23 (6.7%) 152 (44.1%)		
First line treatment	Treatment modality other than surgery	Chemotherapy Chemo-radiation Target agents	215 (62.3%) 75 (21.7%) 55 (15.9%)	
	Purpose of the treatment	Neoadjuvant Adjuvant Definitive Palliative	6 (1.7%) 170 (49.3%) 15 (4.3%) 154 (44.6%)	

## Supplementary Table S2: Baseline characteristics of patients from 2<sup>nd</sup> data set

Patients' characteristics	Number (%)			
Age, years	Median (IQR, range)	58 (15, 27–82)		
Gender	Male Female	27 (69.2%) 12 (30.8%)		
Disease	Gastric cancer Biliary tract cancer Lung cancer Lymphoma	11 (28.2%) 6 (15.4%) 18 (46.2%) 4 (10.3%)		
Metastasis**	Yes No	31 (88.6%) 4 (11.4%)		
Chemotherapy within 6 months	Yes No	26 (66.7%) 13 (33.3%)		
Hemoglobin (g/dL)	Median (IQR)	9.5 (6.2)		
MCV (fL)	Mean± SD	$92.2 \pm 1.3$		

Abbreviates: MCV, mean corpuscular volume; SD, standard deviation; IQR, interquartile range

<sup>\*\*</sup>Lymphoma patients (n = 4) were excluded from the analysis

#### **Supplementary Table S3: Biochemical parameters in cancer patients**

				General population	Population in this study
	Women	Mean	Premenopausal	53	$224.7 \pm 78.3^*$
			Post-menopausal	105	
Ferritin, ng/mL		Range	Premenopausal	6–180	7.5–930.9
remun, ng/ml			Post-menopausal	8–350	
	Men	Mean		175	$240.7 \pm 36.1^*$
		Range		20–400	2.1–611.9
-T(D /I	Mean			0.854	$1.03 \pm 0.09$
sTfR, ug/mL	Range			0.072-1.699	0.36–2.63
CRP, mg/L	Mean			_	$14.73 \pm 4.10$
	Median			_	3.42 (13.95**)
	Range			0.068-8.2	0.01-100.00
Hanaidin na/mI	Mean			10.1	$12.50 \pm 1.78^*$
Hepcidin, ng/mL	Median			7.2	9.52 (16.18**, 1.19–50.33)

<sup>\*</sup>Standard deviation (SD)

<sup>\*\*</sup>Interquartile range (IQR)

# Supplementary Table S4: Correlation between conventional iron parameters and cancer anemia related parameters

4–1

			No anemia $(n = 18)$	Anemia $(n = 21)$	<i>p</i> -value
Biochemical parameters	Ferritin, ng/mL	Median (IQR)	$166.7 \pm 29.7$	$295.0 \pm 55.5$	0.050
	Iron	67.31+/-8.39 55.00 (74, 9-156)	89.5 (59, 37–139)	37 (62, 9–156)	0.024
	TIBC	275.0 (136, 164–435)	322.5 (114, 225–386)	266 (184, 164–435)	0.352
	TS	25.30 (20.2, 2.8–43.7)	29.6 (12.8, 15.6–40.6)	14.3 (24.7, 2.8–43.7)	0.069

4–2

		Ferritin		sTfR		Cl	CRP		Hepcidin		Hemoglobin	
		r	<i>p</i> -value	r	<i>p</i> -value	r	<i>p</i> -value	r	<i>p</i> -value	r	<i>p</i> -value	
Conventional iron TIBC parameters TS	Iron	_	0.951	_	0.063	-0.559	0.002	_	0.822	0.437	0.018	
	TIBC	-0.698	<0.000	_	0.289	-0.497	0.006	-0.654	<0.001	_	0.696	
	TS	_	0.179	_	0.187	-0.441	0.017	_	0.189	0.400	0.031	